FDA names reproductive/urologic drug division head
FDA Division of Reproductive & Urologic Drug Products Acting Director Daniel Shames, MD, is named permanent division head. He has been acting director since October. The division's focus under Shames could be female sexual dysfunction and andropause (1"The Pink Sheet" March 18, p. 18). Shames is a member of FDA's Oncology Coordinating Committee and Shelf-Chemical working group...
You may also be interested in...
A focus of FDA's Reproductive & Urologic Drug Products Division under Acting Director Daniel Shames, MD, could be female sexual dysfunction and andropause
Legal experts tell the Pink Sheet why India’s plans to abolish the Intellectual Property Appellate Board and shift its powers to courts may be problematic for stakeholders, including those pursuing infringement charges. The transition could mean a significant burden on courts both in terms of capability and capacity, and IPR cases will now conflate into all other pending commercial matters, some experts said, though others cheered the proposed change.
Tyto Care’s remote monitoring and telehealth platform has seen rising demand since the start of the pandemic and the company continues to expand. This week, it announced it raised $50m in a series D financing round. See what Dedi Gilad, CEO of Tyto Care, said about it here.